Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Safis Biotech is a biotechnology company specializing in the development of cost-effective recombinant proteins for bone regeneration and orthopedic applications. The company's core technology is a proprietary yeast-based expression system used to produce recombinant human Bone Morphogenetic Protein-2 (rhBMP-2), which is traditionally manufactured using more expensive mammalian cell cultures. Safis Biotech aims to provide high-quality, affordable growth factors for use in spinal fusions, fracture repairs, and dental procedures. By leveraging its unique production platform, the company seeks to improve patient access to advanced regenerative therapies while maintaining high biological activity and safety standards. Their lead candidate, Safis-BMP-2, is designed to offer a more scalable and economical alternative to existing bone graft substitutes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Safis Biotech.